Karyopharm announces preliminary unaudited 2024 revenue and 2025 objectives

– opportunity to define a new myelofibrosis treatment paradigm with top-line data readout from phase 3 sentry trial evaluating selinexor in combination with ruxolitinib in patients with jaki-naÏve myelofibrosis anticipated in 2h 2025; company on track to complete enrollment in 1h 2025 –  – recently announced key leadership changes, including the appointment of lori macomber as chief financial officer and brendan strong as svp of investor relations and corporate communications –  – preliminary unaudited full year 2024 total revenue and u.s. xpovio® (selinexor) net product revenue expected to be approximately $145 million and $113 million, respectively – newton, mass. , jan. 13, 2025 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and u.s. xpovio net product revenue estimates and outlined its 2024 achievements and 2025 objectives.
KPTI Ratings Summary
KPTI Quant Ranking